Italian oncologists will be able to predict the severity of breast cancer at a very early stage thanks to Catalan technology. Inbiomotiona company that emerged as a result of research carried out at IRB Barcelona and ICREAhas reached an agreement with the Farmacéutica Italiana SPA Farma so that this company is the one that distributes its MAF Test in the transalpine country. Thus, the Barcelona-based company manages to take its proposal to a fifth market, after sealing alliances of this style in Spain (con Palex), he Sub-Saharan Africa (con The Scientific Group) and in United Kingdom e Ireland (con Source Biosciences).
“The MFA Test predicts the prognosis of patients with breast cancer and helps the oncologist identify those in whom recurrence could be prevented and benefit from adjuvant treatment with bisphosphonates.commonly used to treat osteoporosis,” contextualizes this in a statement. ‘biotech’ led by Dr. Roger Gomis y financed, among others, by Ysios Capital, Caixa Capital Risc, Alta Life Sciences and the Vila Casas Foundation. “The test also identifies those patients whose prognosis would worsen if they were treated or were being treated with bisphosphonates,” he adds.
In short, much more information for the doctor in a field where it is critical to have it. “Having the ability to identify patients with the highest risk of recurrence and being able to personalize their treatment is vital for their survival and quality of life,” they explain from Inbiomotion, which is based on the fact that This is the most common cancer among women and new diagnoses amount to 2 million each year around the world..
The power of SPA Farma
The partner chosen to deploy its shield against this in Italy is not minor. It is about a family pharmaceutical company founded by physiologist Rodolfo Ferrari and today led by his granddaughter, Alisée Matta Echaurren. The company is known in Italy for being one of the first to produce and market penicillin in the country during the post-war periodan achievement that was achieved thanks to scientific collaboration with the Alexander Fleming.
“We believe that this partnership with SPA Farma will play a crucial role in achieving our objectives in the Italian market,” summarizes the CEO of Inbiomotion and also CEO of Ysios Capital, Joël Jean-Mairet. “This collaboration represents an important step forward in bringing precision medicine to more patients,” he added. “By offering a personalized approach to cancer treatment, we can significantly improve patient outcomes, reduce the likelihood of unnecessary treatments and , ultimately improving the quality of life of those fighting breast cancer.”
